Delyon J et al.
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Journal of Investigative Dermatology 2018 138(1)
doi: 10.1016/j.jid.2017.07.839